ACNS1831 - Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG) (CRADA 02172)

Grant

Awarded By

Total Award Amount

  • 3750.00

    • Direct Costs

  • 2757.00

    • Sponsor Award Id

    • Contributor

  • Elizabeth Alva   Investigator  
  • Girish Dhall   Investigator  
  • Gregory Friedman M.D.   Investigator  
  • Laura Metrock   Principal Investigator